Date: July 8, 2021
Time: 8:00am (PDT)
Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several FDA approved products already on the market. There has been tremendous effort to make CAR T cells more effective, safe, and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation, and contamination can be associated with open processes and manual handling of CAR T cells. In this talk, we will discuss a closed cell therapy manufacturing workflow developed by Thermo Fisher Scientific. This GMP compliant, semi-automated manufacturing platform, which when used in combination with Gibco™ Cell Therapy System™ (CTS™) reagents, protocols, and analytics, can result in efficient, consistent, regulatory-compliant manufacture of CAR T cell product. Taken together with instrument modularity, digital connectivity, and cGMP compatibility, the manufacturing of therapeutic CAR T cells using this workflow will help enable a lower rate of contamination, less product failure, and higher product consistency. Please join us to learn more about various solutions that Thermo Fisher Scientific can offer to support customers who plan to manufacture of CAR T cells for clinical use.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.